These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 18398661)
1. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective. Kulkarni S; Hicks DG Ann Surg Oncol; 2008 Jun; 15(6):1677-88. PubMed ID: 18398661 [TBL] [Abstract][Full Text] [Related]
2. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Chang HR Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392 [TBL] [Abstract][Full Text] [Related]
3. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer? Constantinidou A; Smith I Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Baselga J; Perez EA; Pienkowski T; Bell R Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734 [TBL] [Abstract][Full Text] [Related]
5. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613 [TBL] [Abstract][Full Text] [Related]
6. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. Montemurro F; Aglietta M Clin Breast Cancer; 2005 Apr; 6(1):77-80. PubMed ID: 15899075 [TBL] [Abstract][Full Text] [Related]
7. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Goldenberg MM Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534 [TBL] [Abstract][Full Text] [Related]
8. Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era. Palmieri C; Shah D; Krell J; Gojis O; Hogben K; Riddle P; Ahmad R; Tat T; Fox K; Porter A; Mahmoud S; Kirschke S; Shousha S; Gudi M; Coombes RC; Leonard R; Cleator S Clin Breast Cancer; 2011 Apr; 11(2):93-102. PubMed ID: 21569995 [TBL] [Abstract][Full Text] [Related]
9. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Brufsky A Am J Clin Oncol; 2010 Apr; 33(2):186-95. PubMed ID: 19675448 [TBL] [Abstract][Full Text] [Related]
10. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921 [TBL] [Abstract][Full Text] [Related]
11. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Bedard PL; Piccart-Gebhart MJ Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S157-65. PubMed ID: 19158036 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Jahanzeb M Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259 [TBL] [Abstract][Full Text] [Related]
13. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853 [TBL] [Abstract][Full Text] [Related]